Shanmugam Muthusamy's Form 4 filing

Ani Pharmaceuticals Inc (ANIP) · filed Apr 22, 2024

Accession no.: 0001870913-24-000016
Filed: Apr 22, 2024
Trade date: Apr 18-19, 2024
Filing delay: 4 days
Rule 10b5-1 plan: Checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $1.77M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Shanmugam MuthusamyCIK 0001870913	Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Apr 18, 2024	Common Stock	SSaleDisposed	−10,423	$64.98^F2	−$677,286.54	799,429	Indirect
Apr 19, 2024	Common Stock	SSaleDisposed	−16,809	$65.17^F4	−$1,095,442.53	782,620	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The shares were sold in multiple trades at prices ranging from $64.43 to $65.89. The price reported above reflects the weighted average sales price.

Referenced by the price of 1 transaction in Table I.

The shares were sold in multiple trades at prices ranging from $64.20 to $65.79. The price reported above reflects the weighted average sales price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)